Clinical trials: Hepatocellular Carcinoma (HCC), open to volunteers
HCC - Hepatocellular Carcinoma
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the…
- Trial name
- NCT07157969
- Testing
- Lenvatinib, Pembrolizumab, Atezolizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Solid Tumor
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer…
- Trial name
- NCT06938880
- Testing
- ZGGS18 for Injection, ZG005 for Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Liver Cirrhosis
Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial
This clinical trial is testing whether taking a low dose aspirin tablet (100 mg) once a day can help prevent liver cancer (hepatocellular carcinoma, HCC) in people who have cirrhosis, which is severe scarring of the liver.
- Trial name
- AspiRe HCC (NCT07529262)
- Testing
- Low-dose aspirin
- Volunteers
- 890 people
- Sponsor
- Curtin University
Hepatocellular Carcinoma
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy.
- Trial name
- NCT07078305
- Testing
- Regorafenib and tislelizumab, Regorafenib
- Volunteers
- 134 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Prognostic Biomarker, Liver Transplantation
Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma
Liver transplantation (LT) is the only curative option for a selection of patients with hepatocellular carcinoma (HCC) based on clinical selection criteria known as the Milan criteria.
- Conditions
- Prognostic Biomarker, Liver Transplantation, Diagnostic Biomarker, Hepatocellular Carcinoma
- Trial name
- GLITCA (NCT05866783)
- Testing
- HCCRecurrencePrognosticScore, HCCRecurrenceDiagnosticScore
- Where
- Belgium
- Volunteers
- 500 people
- Sponsor
- University Hospital, Ghent
Hepatocellular Carcinoma
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
- Trial name
- (HCC) (NCT06789757)
- Testing
- Memantine Hydrochloride, Bevacizumab, Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Inova Health Care Services
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Hepatocellular Carcinoma (HCC)
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment…
- Trial name
- NCT07303712
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Palo Alto Veterans Institute for Research
Cirrhoses, Liver, Carcinoma Liver
ProspEXPO : Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome
The aim of the study is to build up a bio-collection of biological samples from patients with cirrhosis. Further work using this bio-collection will permit to describe the influence of different exposome factors (nutrition…
- Trial name
- ProspEXPO (NCT07119957)
- Testing
- Blood, urine and stool biocollection
- Where
- 4 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Angers
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
- Trial name
- NCT07164313
- Testing
- ZW251
- Where
- 25 sites in United States, Ireland and 4 more
- Volunteers
- 140 people
- Sponsor
- Zymeworks BC Inc.
Hepatocellular Carcinoma (HCC)
Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment
This study plans to enroll 704 patients with a history of chronic hepatitis B who have undergone radical treatment for hepatocellular carcinoma.
- Trial name
- BRCSRRRHCCART (NCT06923176)
- Testing
- Biejia-Ruangan compound, Routine medical care
- Volunteers
- 704 people
- Sponsor
- Zhiyun Yang
Hepatocellular Carcinoma
A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma
350 new cases of hepatocellular carcinoma (HCC) are diagnosed in Denmark each year, but the overall prognosis is poor with a 1-year survival rate of less than 40% and a 5-year survival rate of 10% for the entire patient group.
- Trial name
- NCT05203120
- Testing
- Proton therapy
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.
The project aims to collect blood, tissue samples, and clinical data from patients with primary liver cancer (mainly hepatocellular carcinoma and intrahepatic cholangiocarcinoma) undergoing systemic therapy, surgical resection…
- Trial name
- NCT06899854
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, Metabolic Syndrome
- Trial name
- PROMETEO (NCT04371042)
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Liver Transplantation, Hepatocellular Carcinoma
Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
Hepatocellular Carcinoma (HCC) is the most common liver malignancy and the third leading cause of cancer death worldwide. Due to the shortage of donor organs and the risk of tumor recurrence after transplantation, the restrictive…
- Trial name
- NCT05475613
- Testing
- Downstaging procedures containing immunotherapy, Liver transplantation
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
- Trial name
- NCT07691762
- Testing
- SHR-8068 + Adebrelimab + Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 690 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Solid Tumor
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
This is a correlative research project aimed at characterizing the T cell mediated immune responses to hepatocellular carcinoma (HCC), as well as Epstein-Barr virus (EBV)- and human papillomavirus (HPV)-related cancers.
- Trial name
- LANDMARC (NCT04665388)
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma (HCC)
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
- Trial name
- GPC3 (NCT06726161)
- Testing
- RYZ811, RYZ801
- Where
- 13 sites in United States
- Volunteers
- 590 people
- Sponsor
- RayzeBio, Inc.
Hepato Cellular Carcinoma, Cirrhosis
PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)
Chronic liver diseases affect 1.5 billion people worldwide and can lead to cirrhosis and hepatocellular carcinoma (HCC), which ranks as the third leading cause of cancer-related mortality globally.
- Conditions
- Hepato Cellular Carcinoma, Cirrhosis, Autonomic Nervous System, Central Nervous System
- Trial name
- PSYLIVER-PILOT (NCT07393074)
- Testing
- Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation., Self-administered questionnaires to assess psycho-behavioral traits, Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night.
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Carcinoma, Hepatocellular Carcinoma
A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)
This is a prospective, single-arm Phase II study designed to evaluate the safety and efficacy of carbon ion radiotherapy in patients with hepatocellular carcinoma (HCC) who demonstrate residual or recurrent disease after prior…
- Trial name
- NCT07252323
- Testing
- Carbon Ion Radiotherapy
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University